Dr. Marcom Reflects on Field of HR+ Breast Cancer

Paul Kelly Marcom, MD
Published: Friday, Oct 21, 2016



Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses how the field of hormone receptor (HR)-positive breast cancer has evolved in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

This has clearly been an area that has exploded over the last 5 years due to the developments of targeted therapies in combination with standard endocrine therapy, which has been translated into significant clinical benefit for patients, Marcom explains. The approval of everolimus (Afinitor) marked a step forward in the disease; however, with developments of CDK 4/6 inhibitors, such as palbociclib (Ibrance), there has been even more improved outcomes.

These advancements point to a different part of the biology of breast cancer, he adds. Next steps will involve exploring unique combinations and researching how to sequence them, he adds.


Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses how the field of hormone receptor (HR)-positive breast cancer has evolved in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.

This has clearly been an area that has exploded over the last 5 years due to the developments of targeted therapies in combination with standard endocrine therapy, which has been translated into significant clinical benefit for patients, Marcom explains. The approval of everolimus (Afinitor) marked a step forward in the disease; however, with developments of CDK 4/6 inhibitors, such as palbociclib (Ibrance), there has been even more improved outcomes.

These advancements point to a different part of the biology of breast cancer, he adds. Next steps will involve exploring unique combinations and researching how to sequence them, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x